Elan Corporation Plc expects to see revenue grow by double-digit figures in 2009 after a strong first half during which its biopharmaceutical revenues, including sales of the multiple sclerosis drug, Tysabri, rose by 21.4%. ---Subscribe to MedNous to access this article--- Company News
